BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a buy rating in a research report report published on Tuesday.

Other equities research analysts also recently issued reports about the stock. Zacks Investment Research downgraded shares of Deciphera Pharmaceuticals from a buy rating to a hold rating in a research note on Monday. Nomura began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. Piper Jaffray Companies began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an overweight rating and a $35.00 price objective on the stock. JMP Securities began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued an outperform rating and a $38.00 price objective on the stock. Finally, Instinet began coverage on shares of Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They issued a buy rating and a $57.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, The company currently has an average rating of Buy and an average price target of $40.83.

Shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) traded up $0.59 on Tuesday, reaching $25.66. 134,562 shares of the company traded hands, compared to its average volume of 185,686. Deciphera Pharmaceuticals has a 1 year low of $15.15 and a 1 year high of $26.59. The stock has a market cap of $820.98 and a P/E ratio of -6.48.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, November 14th. The company reported ($5.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($5.30). analysts anticipate that Deciphera Pharmaceuticals will post -2.91 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Pura Vida Investments LLC purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at $1,329,000. Perceptive Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at $1,946,000. Orbimed Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at $7,487,000. Alyeska Investment Group L.P. purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at $1,968,000. Finally, Citadel Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals in the 3rd quarter valued at $4,965,000. 43.94% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/deciphera-pharmaceuticals-dcph-raised-to-buy-at-bidaskclub/1801737.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.